Sarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion.

Core Viewpoint - Sarepta Therapeutics is facing a class action lawsuit due to alleged misleading statements and undisclosed safety risks related to its gene therapy product ELEVIDYS, which has resulted in significant stock price declines following patient deaths and regulatory scrutiny [3][4][5][6][7]. Group 1: Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for Duchenne muscular dystrophy, including the gene therapy product ELEVIDYS [3]. Group 2: Allegations and Legal Actions - The class action lawsuit claims that Sarepta made false or misleading statements regarding ELEVIDYS, including significant safety risks and inadequate clinical trial protocols [3]. - The lawsuit highlights that adverse events related to ELEVIDYS forced Sarepta to pause recruitment and dosing in trials, which jeopardized regulatory approvals [3]. Group 3: Stock Price Impact - Following the disclosure of a patient death from acute liver failure on March 18, 2025, Sarepta's stock dropped more than 27% [4]. - An additional announcement on April 4, 2025, regarding a review by European regulatory authorities led to a further 7% decline in stock price [5]. - A second patient death reported on June 15, 2025, caused the stock price to decline over 42% [6]. - The FDA's Safety Communication on June 24, 2025, regarding the investigation of patient deaths resulted in an additional 8% drop in Sarepta's stock [7].